Advanced interstitial lung disease: Evidence-based management and clinical approach
Keywords:
interstitial lung diseases, pulmonary fibrosis, advanced lung disease, disease management, evidence-based practiceAbstract
Background: Interstitial lung disease (ILD) is a heterogeneous group of diseases characterized by clinical, physiologic, and radiologic abnormalities. Advanced ILD (sometimes referred to as end-stage interstitial lung disease) is characterized by either gradual or rapid progressive decline of pre-existing or newly diagnosed ILD with worsening of symptoms, pulmonary function tests, six-minute walk test (6MWT) distance, and/or imaging findings, specifically high-resolution computed tomography (HRCT) imaging of the chest affecting patient’s quality of life. Special considerations are required for the management of patients with these advanced ILDs, particularly those who will ultimately require lung transplantation. Though several society and expert panels provide guidance on ILD management, there are none focused specifically on the approach to patients with advanced ILD.
Objectives: In this review, we attempt to define advanced ILD and identify the clinical considerations required for diagnosis and management of patients with advanced ILD.
Discussion: Pathophysiologic mechanisms of ILD and complications are not completely understood but include inflammation, fibrosis, pulmonary hypertension, venous thromboembolism, recurrent infections, and aspiration. Management of these patients includes consideration of anti-fibrotic medications, anti-inflammatory/immunosuppressive medications and treatment of concurrent pulmonary hypertension as indicated on a case-by-case basis. Non-pharmacologic management with supplemental oxygen, pulmonary rehabilitation, and palliative care are tailored to each patient’s clinical status. Finally, early referral to lung transplantation is critical, as advanced ILD can be fatal, and sometimes rapidly so.
Conclusion: Advanced ILD is an oftentimes fatal group of heterogeneous diseases that have varying managements depending on underlying subtype. Identification of progressive disease and complications are the first steps to management of these patients to optimize lung function and quality of life and improve outcomes before lung transplantation.
References
1. Cottin V, Teague R, Nicholson L, Langham S, Baldwin M. The burden of progressive-fibrosing interstitial lung diseases. Front Med (Lausanne). 2022;9:799912. doi: 10.3389/fmed.2022.799912.
2. Walsh SLF, Devaraj A, Enghelmayer JI, et al. Role of imaging in progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27(150):180073. doi: 10.1183/16000617.0073-2018.
3. Leong SW, Bos S, Lordan JL, Nair A, Fisher AJ, Meachery G. Lung transplantation for interstitial lung disease: evolution over three decades. BMJ Open Respir Res. 2023;10(1):e001387. doi: 10.1136/bmjresp-2022-001387.
4. Zhang N, Liu S, Zhang Z, Liu Y, Mi L, Xu K. Lung transplantation: A viable option for connective tissue disease? Arthritis Care Res (Hoboken). 2023;75(11):2389-2398.
5. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431-440. doi: 10.1164/rccm.201006-0894CI.
6. Gupta R, Judson MA, Baughman RP. Management of advanced pulmonary sarcoidosis. Am J Respir Crit Care Med. 2022;205(5):495-506. doi: 10.1164/rccm.202106-1366CI.
7. Cottin V, Hirani NA, Hotchkin DL, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27(150):180076. doi: 10.1183/16000617.0076-2018.
8. Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205(9):e18-e47.
9. Faverio P, De Giacomi F, Bonaiti G, et al. Management of chronic respiratory failure in interstitial lung diseases: Overview and clinical insights. Int J Med Sci. 2019;16(7):967-980.
10. Podolanczuk AJ, Wong AW, Saito S, Lasky JA, Ryerson CJ, Eickelberg O. Update in interstitial lung disease 2020. Am J Respir Crit Care Med. 2021;203(11):1343-1352. doi: 10.1164/rccm.202103-0559UP.
11. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis: An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44-e68.
12. Fernandez-Perez ER, Travis WD, et al. Diagnosis and evaluation of hypersensitivity pneumonitis: CHEST guideline and expert panel report. Chest. 2021;160(2):e97-e156. doi: 10.1016/j.chest.2021.03.066.
13. Briganti DF, D'Ovidio F. Long-term management of patients with end-stage lung diseases. Best Pract Res Clin Anaesthesiol. 2017;31(2):167-178. doi: 10.1016/j.bpa.2017.07.007.
14. Flaherty KR, Thwaite EL, Kazerooni EA, et al. Radiological versus histological diagnosis in UIP and NSIP: Survival implications. Thorax. 2003;58(2):143-148. doi: 10.1136/thorax.58.2.143.
15. Asif H, Ribeiro Neto M, Culver D. Pulmonary fibrosis in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2023;40(3):e2023027. Published 2023 Sep 13. doi:10.36141/svdld.v40i3.14830.
16. Bonham CA, Strek ME, Patterson KC. From granuloma to fibrosis: Sarcoidosis-associated pulmonary fibrosis. Curr Opin Pulm Med. 2016;22(5):484-491. doi: 10.1097/MCP.0000000000000301.
17. Trivieri MG, Spagnolo P, Birnie D, Liu P, Drake W, Kovacic JC, Baughman R, Fayad ZA, Judson MA. Challenges in cardiac and pulmonary sarcoidosis: JACC state-of-the-art review. J Am Coll Cardiol. 2020;76(16):1878-1901.
18. Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: Idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med. 2007;175(7):705-711. doi: 10.1164/rccm.200607-912OC.
19. Harari S, Wells AU, Wuyts WA, et al. The 6-min walk test as a primary end-point in interstitial lung disease. Eur Respir Rev. 2022;31(165):220087.
20. Callejas-Moraga EL, Guillén-Del-Castillo A, Perurena-Prieto J, et al. Anti-RNPC-3 antibody predicts poor prognosis in patients with interstitial lung disease associated with systemic sclerosis. Rheumatology (Oxford). 2021;61(1):154-162. doi: 10.1093/rheumatology/keab279.
21. Barratt SL, Davis R, Sharp C, Pauling JD. The prognostic value of cardiopulmonary exercise testing in interstitial lung disease: A systematic review. ERJ Open Res. 2020 Aug;6(3):00027-2020.
22. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684-691. doi: 10.7326/0003-4819-156-10-201205150-00004.
23. Ryerson CJ, Vittinghoff E, Ley B, et al. Predicting survival across chronic interstitial lung disease: The ILD-GAP model. Chest. 2014;145(4):723-728. doi: 10.1378/chest.13-1474.
24. Chandel A, Pastre J, Valery S, King CS, Nathan SD. Derivation and validation of a simple multidimensional index incorporating exercise capacity parameters for survival prediction in idiopathic pulmonary fibrosis. Thorax. 2023;78(4):368-375.
25. Cao H, Huan C, Wang Q, Xu G, Lin J, Zhou J. Predicting survival across acute exacerbation of interstitial lung disease in patients with idiopathic inflammatory myositis: The GAP-ILD model. Rheumatol Ther. 2020;7(4):967-978. doi: 10.1007/s40744-020-00244-1.
26. Mango RL, Matteson EL, Crowson CS, Ryu JH, Makol A. Assessing mortality models in systemic sclerosis-related interstitial lung disease. Lung. 2018;196(4):409-416. doi: 10.1007/s00408-018-0126-6.
27. Nurmi HM, Purokivi MK, Kärkkäinen MS, Kettunen HP, Selander TA, Kaarteenaho RL. Are risk predicting models useful for estimating survival of patients with rheumatoid arthritis-associated interstitial lung disease? BMC Pulm Med. 2017;17(1):16. doi: 10.1186/s12890-016-0358-2.
28. Kobayashi H, Naito T, Omae K, et al. ILD-NSCLC-GAP index scoring and staging system for patients with non-small cell lung cancer and interstitial lung disease. Lung Cancer. 2018;121:48-53.
29. Brusca RM, Pinal-Fernandez I, Psoter K, et al. The ILD-GAP risk prediction model performs poorly in myositis-associated interstitial lung disease. Respir Med. 2019;150:63-65. doi: 10.1016/j.rmed.2019.02.015.
30. Patel DC, Valeyre D. Advanced pulmonary sarcoidosis. Curr Opin Pulm Med. 2020;26(5):574-581.
31. Yu D, Xiang Y, Gou T, Tong R, Xu C, Chen L, Zhong L, Shi J. New therapeutic approaches against pulmonary fibrosis. Bioorg Chem. 2023;138:106592.
32. Shumar JN, Chandel A, King CS. Antifibrotic therapies and progressive fibrosing interstitial lung disease (PF-ILD): Building on INBUILD. J Clin Med. 2021 May;10(11):2285.
33. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071-2082. doi: 10.1056/NEJMoa1402584.
34. King TE, Bradford WZ, Castro-Bernardini S, et al. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2014;370(22):2083–2092. doi: 10.1056/nejmoa1402582.
35. Nathan SD, Costabel U, Glaspole I, et al. Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis. Chest. 2019;155(4):712-719.
36. Vancheri C, Kreuter M, Richeldi L, et al. Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: Results of the INJOURNEY trial. Am J Respir Crit Care Med. 2018;197(3):356-363.
37. Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968-1977. doi: 10.1056/NEJMoa1113354.
38. Morisset J, Johannson KA, Vittinghoff E, et al. Use of mycophenolate mofetil or azathioprine for the management of chronic hypersensitivity pneumonitis. Chest. 2017;151(3):619-625. doi: 10.1016/j.chest.2016.10.029.
39. Interstitial Lung Disease Guideline. ACR. Published August 22, 2023. Available at: https://rheumatology.org/interstitial-lung-disease-guideline.
40. Zekić T. Rituximab as the first-line therapy in anti-synthetase syndrome-related interstitial lung disease. Rheumatol Int. 2023 Jun;43(6):1015-1021.
41. Naccache JM, Montil M, Cadranel J, et al. Study protocol: Exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP). BMC Pulm Med. 2019 Apr 11;19(1):75.
42. Tashkin DP, Roth MD, Clements PJ, et al; Scleroderma Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): A randomized controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708-719. doi: 10.1016/S2213-2600(16)30152-7.
43. Khanna D, Lin CJF, Furst DE, et al. Long-term safety and efficacy of tocilizumab in early systemic sclerosis-interstitial lung disease: Open-label extension of a phase 3 randomized controlled trial. Am J Respir Crit Care Med. 2022;205(6):674-684. doi: 10.1164/rccm.202103-0714OC.
44. Petrov AA, Adatia A, Jolles S, et al. Antibody deficiency, chronic lung disease, and comorbid conditions: A case-based approach. J Allergy Clin Immunol Pract. 2021;9(11):3899-3908.
45. Comes A, Sofia C, Richeldi L. Novel insights in fibrotic pulmonary sarcoidosis. Curr Opin Pulm Med. 2022;28(5):478-484.
46. Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. 2021;58(6):2004079.
47. Posner S, Zheng J, Wood RK, et al. Gastroesophageal reflux symptoms are not sufficient to guide esophageal function testing in lung transplant candidates. Dis Esophagus. 2018;31(5). doi: 10.1093/dote/dox157.
48. Herbella FAM, Patti MG. Gastroesophageal reflux disease and idiopathic lung fibrosis: From heartburn to lung transplant, and beyond. Am Surg. 2022 Feb;88(2):297-302. doi: 10.1177/0003134821998686.
49. Humbert M, Kovacs G, Hoeper MM, et al. ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618-3731. doi: 10.1093/eurheartj/ehac237.
50. Behr J, Nathan SD. Pulmonary hypertension in interstitial lung disease: Screening, diagnosis and treatment. Curr Opin Pulm Med. 2021;27(5):396-404.
51. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006;129(3):746-752.
52. Raghu G, Amatto VC, Behr J, Stowasser S. Comorbidities in idiopathic pulmonary fibrosis patients: A systematic literature review. Eur Respir J. 2015;46(4):1113-1130.
53. Kacprzak A, Tomkowski W, Szturmowicz M. Pulmonary hypertension in the course of interstitial lung diseases—A personalised approach is needed to identify a dominant cause and provide an effective therapy. Diagnostics (Basel). 2023;13(14):2354.
54. Gegenava M, Gegenava T. Association of pulmonary hypertension with outcomes in patients with systemic sclerosis and other connective tissue disorders: Review and meta-analysis. Sarcoidosis Vasc Diffuse Lung Dis. 2024;41(1):e2024023. Published 2024 Mar 26. doi:10.36141/svdld.v41i1.14570.
55. Piccari L, Allwood B, Antoniou K, et al. Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension. Pulm Circ. 2023;13(2):e12213. doi: 10.1002/pul2.12213.
56. Nathan SD. Progress in the treatment of pulmonary hypertension associated with interstitial lung disease. Am J Respir Crit Care Med. 2023;208(3):238-246.
57. King TE Jr, Brown KK, Raghu G, et al. BUILD-3: A randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(1):92-99. doi: 10.1164/rccm.201011-1874OC.
58. Corte TJ, Keir GJ, Dimopoulos K, et al; BPHIT Study Group. Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2014 Jul 15;190(2):208-217. doi: 10.1164/rccm.201403-0446OC. PMID: 24937643; PMCID: PMC4226056.
59. Drakopanagiotakis F, Markart P, Steiropoulos P. Acute exacerbations of interstitial lung diseases: Focus on biomarkers. Int J Mol Sci. 2023;24(12):10196.
60. Khor YH, Renzoni EA, Visca D, McDonald CF, Goh NSL. Oxygen therapy in COPD and interstitial lung disease: Navigating the knowns and unknowns. ERJ Open Res. 2019;5(3):00118-2019.
61. Wallaert B, Kyheng M, Labreuche J, Stelianides S, Wemeau L, Grosbois JM. Long-term effects of pulmonary rehabilitation on daily life physical activity of patients with stage IV sarcoidosis: A randomized controlled trial. Respir Med Res. 2020;77:1-7.
62. Pawlow PC, Blumenthal NP, Christie JD, Matura LA, Aryal S, Ersek M. An integrative review of the role of palliative care in lung transplantation. Prog Transplant. 2021;30(2):147-154.
63. Palmer E, Kavanagh E, Visram S, Bourke AM, Forrest I, Exley C. When should palliative care be introduced for people with progressive fibrotic interstitial lung disease? A meta-ethnography of the experiences of people with end-stage interstitial lung disease and their family carers. Palliat Med. 2022;36(8):1171-1185. doi: 10.1177/02692163221101753.
64. Kalluri M, Lu-Song J, Younus S, et al. Health care costs at the end of life for patients with idiopathic pulmonary fibrosis: Evaluation of a pilot multidisciplinary collaborative interstitial lung disease clinic. Ann Am Thorac Soc. 2020;17(6):706-713.
65. Khush KK, Cherikh WS, Chambers DC, et al; International Society for Heart and Lung Transplantation. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report - 2019; focus theme: Donor and recipient size match. J Heart Lung Transplant. 2019;38(10):1056-1066. doi: 10.1016/j.healun.2019.08.004.
66. Hsich E, Singh TP, Cherikh WS, et al; International Society for Heart and Lung Transplantation. The International thoracic organ transplant registry of the International Society for Heart and Lung Transplantation: Thirty-ninth adult heart transplantation report-2022; focus on transplant for restrictive heart disease. J Heart Lung Transplant. 2022;41(10):1366-1375.
67. Ahya VN, Diamond JM. Lung transplantation. Med Clin North Am. 2019;103(3):425-433.
68. Mannem H, Aversa M, Keller T, Siddhartha G. The lung transplant candidate, indications, timing, and selection criteria. Clin Chest Med. 2023;44(1):15-33.
69. Lian QY, Chen A, Zhang JH, et al. Lung transplantation for anti-MDA5-positive dermatomyositis-associated rapid progressive interstitial lung disease: Report of two cases and review of the literature. Clin Rheumatol. 2023;42(3):941-947.
70. Meyer KC. Lung transplantation for pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2019;36(2):92-107. doi: 10.36141/svdld.v36i2.7163.
71. van der Mark SC, Hoek RAS, Hellemons ME. Developments in lung transplantation over the past decade. Eur Respir Rev. 2020;29(157):190132.
72. Crespo MM, Claridge T, Domsic RT, et al. ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part III: Pharmacology, medical and surgical management of post-transplant extrapulmonary conditions statements. J Heart Lung Transplant. 2021;40(11):1279-1300.
73. Leard LE, Holm AM, Valapour M, et al. Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2021;40(11):1349-1379. doi: 10.1016/j.healun.2021.07.005.
74. Bos S, De Sadaleer LJ, Vanstapel A. Antifibrotic drugs in lung transplantation and chronic lung allograft dysfunction: A review. Eur Respir Rev. 2021;30(160):210050.
75. Tanaka S, Miyoshi K, Higo H. Lung transplant candidates with idiopathic pulmonary fibrosis and long-term pirfenidone therapy: Treatment feasibility influences waitlist survival. Respir Investig. 2019;57(2):165-171.
76. De Sadeleer LJ, Verleden SE, Vos R, Van Raemdonck, Verleden GM. Advances in lung transplantation for interstitial lung diseases. Curr Opin Pulm Med. 2020;26(5):518-525.
77. Cheng W, Zeng Y, Wang D. Stem cell-based therapy for pulmonary fibrosis. Stem Cell Res Ther. 2022;13(1):492.
78. Andreikos D, Karampitsakos T, Tzouvelekis A, Stratakos G. Statins' still controversial role in pulmonary fibrosis: What does the evidence show? Pulm Pharmacol Ther. 2022;102168.
Downloads
How to Cite
Issue
Section
License
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
